There are several subsets of triple negative breast cancer.
cancer studies Triple negative breast
Triple-negative breast cancer also is unlikely to respond to medicines that target the HER2 protein, such as Herceptin chemical name: trastuzumab , Kadcyla chemical name: T-DMA or ado-trastuzumab emtansine , Nerlynx chemical name: neratinib , Perjeta chemical name: pertuzumab , or Tykerb chemical name: lapatinib. Your friend's email. Help us endcancer. Chemotherapy is still an effective option for treating this cancer and reducing the risk of its return. If your cancer hasn't metastasized, ask if you need surgery or chemo first.
The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. Your message to the editors. In addition, there are many clinical trials underway looking at new treatment options for patients with triple negative breast cancer.